|Dr Kevin Gillinder|
Dr Kevin Gillinder is in Professor Andrew Perkins' research group at the Australian Centre for Blood Diseases, Monash University, He is investigating the role of JAK2 gene mutations in causing blood cancer.
JAK2 is one of the acquired gene mutations found in MPNs and people with this mutation have a higher risk of developing AML. Looking at the genetic sequences of people with MPNs may help to identify a target for treatment of myelproliferative neoplasms (MPN)s. Patients live with debilitating symptoms and harsh side effects, as current treatments aim to reduce the risks of bleeds or clots but do not prevent the risk of disease progression to acute myeloid leukaemia (AML) or myelofibrosis and there is currently no cure.
“The focus is on supporting research that will have a direct impact on understanding the drivers of disease progression inMPNs and identifying new targets in the pursuit of breakthrough treatments” said Dr Laura Issa, Non-Executive Director for The Ruby Red Foundation.